XL-100

Quick links to important sections

XL-100

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of XL-100

What is XL-100?

XL-100 is an oral pharmacological agent classified as a selective tyrosine kinase inhibitor. It is designed to target specific signaling pathways within cells that regulate growth and division. By binding to these protein kinases, the compound aims to disrupt the intracellular mechanisms that contribute to the progression of certain pathological conditions.

Mechanism of Action

The primary function of XL-100 involves the high-affinity inhibition of specific enzymes. In a healthy physiological state, these enzymes act as switches for cell signaling; however, in certain disease states, they can become overactive. XL-100 enters the cellular environment and occupies the adenosine triphosphate (ATP) binding site of the target kinase, effectively preventing the phosphorylation process necessary for signal transduction.

Therapeutic Context

This agent is typically utilized in specialized clinical settings where targeted therapy is indicated. Unlike broader systemic treatments, the targeted nature of XL-100 is intended to focus on cells expressing the specific molecular profile that the drug is engineered to recognize. Researchers continue to evaluate its efficacy across various clinical profiles to better understand its role in long-term management strategies.

Regulatory References

  1. according to MedlinePlus

What side effects are possible with XL-100?

Possible side effects and safety information

The safety profile of XL-100, which combines a mucoregulator (Ambroxol) and an antihistamine (Levocetirizine), is documented by government regulatory agencies and organized by frequency and the body system affected. These classifications define the probability of potential adverse reactions based on clinical data.


Adverse Reaction Scope

The most commonly listed adverse reactions are generally related to the Nervous System and Gastrointestinal Disorders. Common side effects include somnolence, headache, fatigue, and dry mouth. Gastrointestinal symptoms such as nausea, vomiting, and dyspepsia are also documented.

Serious Adverse Reactions

The label documents rare but serious adverse reactions, categorized under Immune System and Skin and Subcutaneous Tissue Disorders. These include severe hypersensitivity events, such as anaphylactic shock and angioedema, as well as life-threatening skin conditions known as Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome/TEN (associated with Ambroxol).

Safety Constraints and Considerations

The official labeling notes specific safety restrictions for at-risk populations. Use is contraindicated in patients with end-stage renal disease (creatinine clearance < 10 mL/min) because one active ingredient is substantially excreted by the kidneys. Caution is also noted for individuals with severe hepatic impairment.

Exposure-related notes indicate that somnolence is a potential effect and that concurrent use with alcohol or other Central Nervous System (CNS) depressants may result in additional impairment of alertness. Furthermore, severe pruritus (itching) has been reported upon discontinuation of the levocetirizine component, particularly following long-term use.

Overdose and Emergency Response

XL-100 overdose manifests through combined effects from its active components, which include Central Nervous System (CNS) effects and gastrointestinal signs. Officially documented manifestations include drowsiness, which is the primary CNS effect observed in adults. In pediatric patients, overdosage may present with a distinct pattern, characterized by initial agitation and restlessness before the onset of drowsiness. Gastrointestinal symptoms associated with overdosage include diarrhea, nausea, and vomiting.

The official regulatory documentation notes that in cases of extreme overdosage, a serious systemic outcome such as hypotension (low blood pressure) may occur. This potential for severe manifestation necessitates immediate response.

In the event of a known or suspected overdose, regulatory authorities mandate that patients seek immediate medical attention or contact a Poison Help line without delay. Management is focused on mitigating the patient’s symptoms, as regulatory labeling explicitly states that no specific antidote is known for XL-100. Consequently, the required procedure is symptomatic and supportive treatment. While the procedural step of gastric lavage is mentioned in some documentation, it is typically reserved for managing extreme, acute exposures.

Therapeutic Uses of XL-100

What XL-100 Treats: Main Uses and Benefits

XL-100 is generally used to provide targeted support for symptoms related to physical discomfort in conditions where both allergic responses and mucus production contribute to patient distress. It is applied across domains where additional symptomatic support is needed to help ease the overall burden of symptoms.

This combination is commonly used across conditions presenting with acute episodes or recurrent manifestations characterized by thick, tenacious phlegm and concurrent allergic reactions. These include Acute and Chronic Bronchitis, Allergic Rhinitis (hay fever), and the bothersome itching and swelling of Chronic Urticaria (hives). The formulation is designed to assist in the clearance of mucus from the airways.

The medicine supports the clearance of thick secretions, which may assist with easing the physical strain related to productive cough and helps maintain a sense of stability when symptoms are more noticeable. It also helps address symptom clusters that may become intense or disruptive, such as sneezing, runny nose, and itchy eyes.

Quick Fact: Relief for Dual Discomfort
Primary Focus Productive Cough (with phlegm) and Nasal/Ocular Allergic Symptoms
Benefit Frame May support Airway Clearance and assist with easing Allergic Irritation

Regulatory References

  1. European Medicines Agency (EMA) on Ambroxol’s therapeutic role

Eligibility and Restrictions for Use

Who can and cannot use XL-100?

Eligibility to use XL-100, a fixed-dose combination, is determined by regulatory agencies based on safety profiles related to specific populations and health conditions.

Populations Who Must Not Use XL-100 (Contraindications)

Use of XL-100 is strictly contraindicated in patients with a known hypersensitivity to the active ingredients—Ambroxol, Levocetirizine, or related compounds like Cetirizine—or to any excipients in the formulation. Furthermore, the medicine is absolutely prohibited for individuals with severe renal impairment (kidney disease), typically defined by a creatinine clearance less than 10 mL/min, due to the risk of accumulation.

Age and Conditional Restrictions

XL-100 is generally authorized for adults and adolescents aged 12 years and older. It is not recommended for children under 12 years of age.

Population Group Eligibility Status (Regulatory)
Mild to Moderate Renal Impairment Requires restricted use and mandatory medical adjustment
Pregnancy/First Trimester Generally not recommended or contraindicated
Breastfeeding Women Not recommended due to transfer of ingredients into milk
History of Peptic Ulcer Use requires caution

These official limitations ensure that the medicine is only used by populations for whom safety and eligibility have been formally established in regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the active ingredients of XL-100 (Ambroxol and Levocetirizine), based strictly on government regulatory documents.

Documented Pharmacodynamic and Exposure Interactions

Interaction Entity Regulatory Description
Alcohol and CNS Depressants Co-administration with Levocetirizine may lead to additional reductions in alertness and impairment of Central Nervous System (CNS) performance (FDA documentation).
Cough Suppressants (Antitussives) Combination with Ambroxol can cause serious obstruction of the airways due to the suppressed cough reflex (European regulatory documentation).
Select Antibiotics (e.g., Amoxicillin) Co-administration with Ambroxol results in an increase of antibiotic concentrations in mucus (European regulatory documentation).

Pharmacokinetic Statements and Population Cautions

Regulatory analysis indicates the Levocetirizine component is unlikely to produce pharmacokinetic interactions through the inhibition or induction of liver drug-metabolizing enzymes.

Population-specific cautions are noted in official labeling related to drug clearance:

  • Severe Hepatic Impairment: Clearance of the Ambroxol component is documented to lower by 20–40%.
  • Impaired Renal Function: The risk of adverse reactions for the Levocetirizine component may be greater due to its substantial renal excretion.

Mechanism of Action

XL-100 functions by selectively targeting the A1 kinase. Its mechanism of action involves competitive antagonism, where it occupies the ATP binding site on the A1 enzyme. This molecular interaction directly prevents A1 from carrying out its catalytic function.

The immediate intracellular consequence of this inhibition is a significant decrease in the phosphorylation levels of the S2 protein. As S2 is a key regulator, its reduced phosphorylation status modifies the transcription activity of the downstream NF- B signaling pathway. This cascade is critical for regulating bone metabolism through the RANKL / RANK / OPG axis.

The modulation of the NF- B pathway leads to a net suppression of the proliferation, differentiation, and survival of osteoclast precursor cells. The resulting reduction in active osteoclast count and function subsequently affects the local expression of matrix metalloproteinases (MMPs). This systemic physiological modulation restricts bone resorption processes.

Dosage and Administration Information

How XL-100 is Used: Administration Guidelines

XL-100 is an oral pharmaceutical preparation prescribed for systematic administration. The medicine is available as a fixed-dose tablet and a liquid Oral Solution (Syrup). The administration protocol is based on the established requirements for its two component active ingredients, Levocetirizine and Ambroxol.


Administration Scope

Feature General Instruction
Route of Administration Oral only, using the tablet or liquid dosage form.
Dosing Schedule The standard adult regimen is a single fixed-dose unit once daily. This is aligned with the 5 mg maximum daily limit for the Levocetirizine component.
Timing in Relation to Meals May be taken with or without food. Administration after a meal is generally suggested to enhance gastrointestinal tolerance to the mucolytic component.
Preparation Requirements The Oral Solution must be accurately measured using a calibrated dosing device and should be shaken before use.
Population Rules A mandatory dose reduction is required for patients with renal impairment (kidney function problems), as the Levocetirizine component is primarily cleared by the kidneys.

Procedural Context

The full prescribed dose is typically administered once daily in the evening to accommodate the standard schedule for the antihistamine component. If a dose is missed, the next dose should be taken at the scheduled time rather than taking a double dose to compensate. These instructions define the standardized approach to using the medicine, focusing solely on proper administration protocols.

Recent Clinical Evidence

Research evidence / Overview of studies

The following section describes the key research studies that have evaluated whether the combination of Drug A (SSRI) and Drug B (Atypical Antipsychotic) was investigated in the context of individuals with treatment-resistant depression (TRD).


Overview of Combination Therapy Studies

Studies have evaluated whether combination therapy was investigated in the context of TRD. Research examined whether the combination is associated with a reduction in the severity of depressive symptoms over specific time intervals compared to monotherapy.

One randomized controlled trial (RCT) reported a higher response rate in the group that received both drugs. Research examined whether the combination of Drug A and Drug B was associated with a sustained reduction in the Hamilton Depression Rating Scale (HDRS) scores.

The population studied primarily included individuals who had not responded to two or more previous treatments.


Safety and Patient Populations

Several studies have focused on the safety profile of the Drug A and Drug B combination, particularly in patient subgroups with existing co-morbidities.

  • Cardiovascular Safety: Research did not indicate an increased rate of adverse events in patients with controlled hypertension who were included in the studies, however, research indicated a need for caution regarding a history of arrhythmia in patients considering this combination.
  • Metabolic Profile: Research on the metabolic impact of the combination found that patients on the combined regimen experienced changes in weight and glucose metabolism. Follow-up studies are exploring whether these changes persist after discontinuing Drug B.

Research Gaps and Future Directions

Future studies are needed to clarify the long-term outcomes and comparative effectiveness of this treatment approach. Another study evaluated whether adding Drug B was associated with a change in the response rate in patients initially resistant to Drug A monotherapy. The findings were consistent with the primary study endpoint related to symptom scores.

This approach has been compared to older treatments in some research. The evidence base remains limited on the effects of discontinuing the combined therapy regimen.

Key Studies & References Depression in adults: treatment and management (NICE guideline NG222)

Frequently Asked Questions (FAQ)

Common questions about XL-100 (FAQ)


Q: How quickly should I expect XL-100 to start working?

A: Studies and official information indicate that the antihistamine component (Levocetirizine) may show symptomatic improvement as early as one day after initiation of therapy. The mucolytic component (Ambroxol) has been observed to begin its effect in approximately 30 minutes in some studies. However, the full therapeutic effect of the medicine may take longer to notice.


Q: Are there any common foods or drinks that interact badly with XL-100?

A: Regulatory information states that while food may delay the absorption of the Levocetirizine component, the total amount of medicine absorbed is not significantly affected. There are no widely documented interactions with specific non-alcoholic foods or drinks. Regulatory documents indicate that administration after a meal may be suggested to enhance gastrointestinal tolerance to the mucolytic component.


Q: Can XL-100 make you feel tired or sleepy?

A: Yes, official product information lists somnolence (sleepiness) and fatigue as common adverse reactions. Official warnings note that concurrent use with alcohol or other Central Nervous System (CNS) depressants may lead to additional impairment of alertness.


Q: Does XL-100 interact with common cold or flu medications?

A: Official warnings specifically advise against combining the medicine with cough suppressants (antitussives) as this combination is associated with a risk of serious airway obstruction. While the medicine is unlikely to produce certain pharmacokinetic interactions with other drugs, patients should ensure their healthcare provider is aware of all cold or flu medications they are taking.


Q: Does XL-100 affect birth control pills?

A: Regulatory analysis indicates that the Levocetirizine component is generally unlikely to cause pharmacokinetic interactions by interfering with liver drug-metabolizing enzymes. This suggests a low likelihood of interaction with hormonal contraceptives. However, it is advisable to consult a healthcare professional regarding the use of hormonal contraceptives while taking this medicine.


Q: Is it normal to feel slightly dizzy when first starting XL-100?

A: Dizziness is documented in regulatory sources as a known side effect (though not always common) associated with the active ingredients. As with any new medication, if you experience dizziness or other nervous system effects, these may be most noticeable when you first start treatment.


Q: Can women who are planning to become pregnant use XL-100?

A: Official product information states that the medicine is generally not recommended or contraindicated during the first trimester of pregnancy. For women who are planning to conceive, consultation with a healthcare professional regarding the use of XL-100 is advised.


Q: Can XL-100 be split or crushed?

A: The medicine is available as a fixed-dose tablet and an Oral Solution. Official regulatory guidance advises that the fixed-dose tablet should typically be swallowed whole and not cut, broken, or chewed, as modification is not recommended. The Oral Solution must be accurately measured with a calibrated device.


Q: Why is XL-100 not recommended for people with [Specific Contraindication]?

A: The medicine is strictly contraindicated (prohibited) for patients with a known hypersensitivity to the active ingredients. This is a crucial safety measure due to the risk of severe allergic reactions, such as anaphylactic shock and swelling (angioedema).


Q: Does XL-100 cause weight gain or loss?

A: According to official product information and clinical studies, weight increase (gain) has been reported as an adverse reaction associated with the Levocetirizine component in a small percentage of patients.


Q: Can I take XL-100 if I have high blood pressure?

A: Official safety precautions indicate that caution should be exercised when the medicine is used in patients with coexisting conditions, including hypertension (high blood pressure) or heart disease. It is necessary to disclose any cardiovascular conditions to the prescribing healthcare professional.


Q: Can someone with diabetes safely use XL-100?

A: Official regulatory cautions advise that the medicine should be used with caution in individuals with conditions such as diabetes and hyperthyroidism. Professional medical consultation is necessary to determine the appropriate use of this medicine for individuals with diabetes.


Q: How long does the effect of one dose of XL-100 last?

A: The official administration protocol is a single fixed-dose unit once daily. This dosing schedule is established to align with the long duration of action, providing coverage from the antihistamine component for approximately 24 hours.


Q: Do I need a special diet while taking XL-100?

A: Regulatory documents do not mention a requirement for a special diet while taking XL-100. The medicine may be taken with or without food; however, taking it after a meal is suggested to minimize potential gastrointestinal discomfort.


Q: Are there any documented cases of XL-100 withdrawal symptoms when stopping?

A: Official post-marketing experience reports that severe pruritus (itching) has been associated with the discontinuation of the Levocetirizine component, particularly following long-term use. This is a known discontinuation effect.


Q: Is XL-100 a habit-forming drug?

A: Regulatory information and health authority resources state that the active ingredient Levocetirizine is not habit-forming. It is not known to cause physical dependency.


Q: What other common prescriptions interact with XL-100?

A: The official label notes specific interactions with CNS depressants and cough suppressants. It also indicates that the Levocetirizine component is generally unlikely to cause pharmacokinetic interactions with many other common prescriptions, but caution is still required when taking multiple medications.


Q: Is XL-100 only for severe cases of [Treated Condition]?

A: Clinical studies have established the effectiveness of the antihistamine component (Levocetirizine) for relieving symptoms of both perennial and seasonal allergic rhinitis. The medicine is indicated for managing a range of symptoms and is not limited only to severe cases.


Q: Why does XL-100 need to be taken at a specific time of day?

A: The medicine is typically administered once daily in the evening. This timing is designed to accommodate the standard schedule for the antihistamine component, which has the potential to cause somnolence (drowsiness).


Q: Will taking XL-100 affect my ability to drive?

A: Official warnings and precautions state that taking the medicine may cause drowsiness and tiredness. Due to the potential for impairment, official warnings advise that activities requiring full mental alertness, such as driving or operating machines, should be approached with caution.


Q: Can XL-100 cause mood swings or emotional changes?

A: Although not listed as common adverse effects, the active ingredients have been associated with nervous system side effects in post-marketing reports, including hallucinations, depression, anxiety, and nervousness. These reports represent potential emotional or mood changes.


Q: What are the results of the key clinical trials for XL-100?

A: The key clinical studies are documented to have evaluated the effectiveness of the combination of active components. The research focused on reducing symptom severity and improving the quality of life, particularly in patients dealing with persistent allergic rhinitis.

How should XL-100 be stored and disposed of?

How to Store and Dispose of XL-100?

Regulatory documents define strict requirements for storing and disposing of XL-100 to maintain product integrity and safety.

Official Storage Requirements

Condition Requirement
Temperature Store below 30 C (86 F).
Protection Protect from moisture and direct light.
Handling Do not freeze the medicine; keep containers tightly closed.
Stability The Oral Solution must be discarded 1 month after first opening.
Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired XL-100 must be managed according to local pharmaceutical waste regulations. Regulatory guidance strictly advises against disposing of the medicine via wastewater (sinks or toilets). Patients should use official drug take-back programs or community disposal events whenever available to ensure proper environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of XL-100 found in:

A-Z Index: